DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Arthritis Research Program
  4. Research Highlights/News
  5. 2024 Arthritis Research Program

Arthritis Research Program

NEWS RELEASE

Released: July 31, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Arthritis Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Act provides funding for the Arthritis Research Program (ATRP) to support research of high potential impact and exceptional scientific merit focused on reducing the detrimental impact of arthritis on Service members and their retention. Funding for the ATRP will be used to support research on all forms of arthritis. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The ATRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 ATRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY24 ATRP must address one or more of the following focus areas, not all of which will be applicable to every award mechanism:

  • Prevention:
    • Identify or clinically evaluate technologies, solutions or knowledge products for the preventative management of arthritis, especially for post-traumatic osteoarthritis.
  • Diagnosis and Progression Mitigation:
    • Identify factors capable of predicting the onset or progression of disease, especially in understudied populations.
  • Intervention/Treatment:
    • Topic 1: Evaluate interventions or treatment strategies that address the multifactorial burden of arthritis. This may include solutions which address one or more of the following factors: pain or other symptoms, function, psychosocial factors, comorbidities or the pathologic burden of disease.
    • Topic 2: Develop conceptually novel or innovative solutions that address the multifactorial burden of arthritis. This may include solutions which address one or more of the following factors: pain or other symptoms, function, psychosocial factors, comorbidities or the pathologic burden of disease.


Award Mechanism Eligibility Key Mechanism Elements Funding
Clinical Research Award Independent investigators at all academic levels (or equivalent)
  • Supports clinical research that evaluates disease-specific factors and interventions.
  • Research supported by this mechanism is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy.
  • Pre-clinical and animal research are not allowed.
  • Preliminary and/or published data is required.
  • A Clinical Trial Option is available for applications proposing clinical trials.
  • Applications must address one of the following FY24 ATRP Focus Areas:
    • Prevention
    • Diagnosis and Progression Mitigation
    • Intervention/Treatment – Topic 1
  • Base Level
  • Maximum funding of $1.5 million (M) for total costs (direct plus indirect costs)
  • Maximum period of performance is 4 years

  • Clinical Trial Option
  • Maximum funding of $3.0M for total costs (direct plus indirect costs)
  • Maximum period of performance is 4 years
Focused Research Award Independent investigators at all academic levels (or equivalent)
  • Supports conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries and/or improvements in patient care or quality of life for people impacted by arthritis.
  • Clinical research and clinical trials are not allowed.
  • Two research levels, based on the scope of research, are available. It is the responsibility of the Principal Investigator to select the research level that is most appropriate for the proposed study.
  • Preliminary and/or published data, originating from research conducted by the applicant(s) or by other researchers, is required for both levels.
  • The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each research level:
  • Research Level 1: Supports exploratory, high-risk, high-reward research. Early career investigators are particularly encouraged to apply to this research level.
  • Research Level 2: Supports the advancement of pre-clinical research toward clinical translation.
  • Applications must address one of the following FY24 ATRP Focus Areas:
    • Prevention
    • Diagnosis and Progression Mitigation
    • Intervention/Treatment – Topic 2
  • Research Level 1
  • Maximum funding of $500,000 for total costs (direct plus indirect costs)
  • Maximum period of performance is 2 years

  • Research Level 2
  • Maximum funding of $750,000 for total costs (direct plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ATRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil/).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Thursday, August 1, 2024